RhumbLine Advisers
AVIR icon

RhumbLine Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

RhumbLine Advisers’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$424K Buy
91,124
+2,070
+2% +$10.3K ﹤0.01% 2866
2026
Q1 		$479K Sell
89,054
-4,922
-5% -$22.6K ﹤0.01% 2643
2025
Q4 		$335K Sell
93,976
-19,636
-17% -$62.4K ﹤0.01% 2903
2025
Q3 		$329K Sell
113,612
-5,808
-5% -$19.8K ﹤0.01% 2938
2025
Q2 		$430K Buy
119,420
+2,977
+3% +$8.88K ﹤0.01% 2784
2025
Q1 		$348K Sell
116,443
-13,353
-10% -$41.7K ﹤0.01% 2799
2024
Q4 		$435K Sell
129,796
-3,318
-2% -$11K ﹤0.01% 2760
2024
Q3 		$446K Sell
133,114
-4,484
-3% -$16.3K ﹤0.01% 2772
2024
Q2 		$455K Sell
137,598
-4,304
-3% -$16K ﹤0.01% 2750
2024
Q1 		$573K Sell
141,902
-5,214
-4% -$20.4K ﹤0.01% 2578
2023
Q4 		$449K Buy
147,116
+12,808
+10% +$38.8K ﹤0.01% 2728
2023
Q3 		$403K Sell
134,308
-6,747
-5% -$23K ﹤0.01% 2738
2023
Q2 		$528K Buy
141,055
+17,368
+14% +$65K ﹤0.01% 2653
2023
Q1 		$414K Buy
123,687
+5,594
+5% +$22.7K ﹤0.01% 2501
2022
Q4 		$568K Buy
118,093
+1,979
+2% +$10K ﹤0.01% 2404
2022
Q3 		$661K Buy
116,114
+6,402
+6% +$49K ﹤0.01% 2368
2022
Q2 		$779K Buy
109,712
+27,475
+33% +$188K ﹤0.01% 2262
2022
Q1 		$594K Sell
82,237
-4,002
-5% -$27.2K ﹤0.01% 2345
2021
Q4 		$771K Buy
86,239
+547
+0.6% +$8.52K ﹤0.01% 2322
2021
Q3 		$3M Buy
85,692
+3,596
+4% +$99.7K ﹤0.01% 1661
2021
Q2 		$1.76M Buy
82,096
+64,933
+378% +$1.95M ﹤0.01% 2009
2021
Q1 		$1.06M Buy
17,163
+4,647
+37% +$314K ﹤0.01% 2167
2020
Q4 		$523K Buy
+12,516
New +$403K ﹤0.01% 2427

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RhumbLine Advisers's AVIR Position: Q2 2026 in Review

RhumbLine Advisers increased its Atea Pharmaceuticals (AVIR) stake by 2.3% in Q2 2026, buying an estimated $10.3K and bringing the position to 91,124 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

RhumbLine Advisers first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $3M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • RhumbLine Advisers held 91,124 shares of Atea Pharmaceuticals worth $424K as of Q2 2026.
  • RhumbLine Advisers bought 2,070 Atea Pharmaceuticals shares in Q2 2026, an estimated $10.3K.
  • Atea Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2866 holding.
  • RhumbLine Advisers first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • RhumbLine Advisers's Atea Pharmaceuticals position peaked at $3M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.